The effect of 28 days' continuous administration of oral indomethacin on gastroduodenal morphology, gastric mucosal blood flow, and gastric mucosal prostaglandin E2 (PGE2) metabolism in man was studied to define further the mechanisms of mucosal injury induced by indomethacin. Indomethacin caused acute gastroduodenal damage in ali cases, which was maximal at 24 hours of administration. With continued intake, mucosal adaptation occurs resulting in resolution of endoscopic mucosal damage. At the time of maximal mucosal damage, gastric mucosal blood flow was significantly reduced compared with values before treatment (p<0001 in fundus and p<0002 in antrum), with good correlation between the severity of damage and the magnitude of the reduction in blood flow (r=076). Mucosal recovery was associated with a return of the blood flow to normal. PGE2 in mucosal homogenate was significantly reduced by indomethacin in both the hfndus (p<0O01) and antrum (p<001) after 24 hours but there was no correlation between the magnitude of this reduction and the severity of mucosal damage (r=-034). Despite mucosal recovery by 28 days, PGE2 values remained significantly below those before treatment in both the fundus (p<0.01) and antrum (p<0.01). The PGE2 degredation capacity was not influenced by indomethacin. In conclusion, mucosal adaptation to acute damage by indomethacin occurs in man and seems independent of local PGE2 metabolism.
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Abstract
The effect of 28 days' continuous administration of oral indomethacin on gastroduodenal morphology, gastric mucosal blood flow, and gastric mucosal prostaglandin E2 (PGE2) metabolism in man was studied to define further the mechanisms of mucosal injury induced by indomethacin. Indomethacin caused acute gastroduodenal damage in ali cases, which was maximal at 24 hours of administration. With continued intake, mucosal adaptation occurs resulting in resolution of endoscopic mucosal damage. At the time of maximal mucosal damage, gastric mucosal blood flow was significantly reduced compared with values before treatment (p<0001 in fundus and p<0002 in antrum), with good correlation between the severity of damage and the magnitude of the reduction in blood flow (r=076). Mucosal recovery was associated with a return of the blood flow to normal. PGE2 in mucosal homogenate was significantly reduced by indomethacin in both the hfndus (p<0O01) and antrum (p<001) after 24 hours but there was no correlation between the magnitude of this reduction and the severity of mucosal damage (r=-034). Despite mucosal recovery by 28 days, PGE2 values remained significantly below those before treatment in both the fundus (p<0.01) and antrum (p<0.01). The PGE2 degredation capacity was not influenced by indomethacin. In conclusion, mucosal adaptation to acute damage by indomethacin occurs in man and seems independent of local PGE2 metabolism.
It is well known that non-steroidal antiinflammatory drugs (NSAIDs), extensively used as simple analgesics and in rheumatic diseases, cause gastrointestinal injury, particularly in the stomach and proximal small bowel. 1-' The damage produced can result in serious complications such as ulceration, bleeding, and perforation, which can be life threatening. ' How NSAIDs cause gastroduodenal damage is unknown, although the depletion of mucosal prostaglandins, which reduces the competence of the mucosal defence mechanisms, is thought to be of major importance.7 Support for this mechanism is provided by the findings that NSAIDs reduce many apsects of mucosal defence such as epithelial HCO3 secretion,'0 mucus synthesis and secretion," 12 and surface hydrophobicity'3 -effects largely prevented by treatment beforehand with prostaglandin. In addition to their effects on mucosal defence, NSAIDs also reduce the integrity of the 'mucus cap', produced in response to superficial injury, which is important in providing a suitable environment for epithelial repair to take place. '4 The effects ofNSAIDs on mucosal blood flow, a vital component of mucosal defence and repair, remain controversial. Ashley et all' have shown that asprin causes a reduction in gastric mucosal blood flow at the sites ofdamage, with augmentation of blood flow elsewhere, and an overall increase in gastric blood flow. Main and Whittle'6 observed reduced basal gastric mucosal blood flow in rats after doses of indomethacin that inhibited prostaglandin formation, while Kaufman'7 found a decrease in basal gastric mucosal blood flow in conscious dogs given indomethacin. Studies in man by Konturek'8 have suggested that indomethacin reduces basal gastric mucosal blood flow. These and other findings suggest that endogenous prostaglandins contribute to the maintenance of basal gastric mucosal blood flow in animals and man. 19 The incidence of serious side effects with NSAIDs, however, is low considering the large numbers of these drugs prescribed.20 Since endoscopic studies have shown acute gastric mucosal damage in most subjects during the first week of NSAID administration,'21 these rather contradictory observations suggest that tolerance develops during the course of continued NSAID intake. This tolerance or adaptation of the gastric mucosa to a variety of damaging agents has been well documented in animal studies,22 and more recently with aspirin23 and indomethacin24 in man. The mechanisms whereby the mucosa develops tolerance to damage, however, remain uncertain.
The aims of our studies were thus threefold: firstly, to document the morphological changes occuring in gastroduodenal mucosa during 28 Before each endoscopy, subjects were questioned directly about gastrointestinal symptoms and in addition kept a detailed written record of the duration, time of day, and severity of any such symptoms between endoscopies.
Ten ml of blood were taken randomly from each subject during the study for later detection of indomethacin to confirm compliance.
Three further subjects were used as controls. These subjects underwent endoscopy with mucosal grading, measurement ofmucosal blood flow, and PGE2 metabolism as above over a 28 day period but received empty indomethacin capsules. The endoscopist was blind to the capsule content.
MORPHOLOGY
At endoscopy, gastric and duodenal integrity Studies on the reproducibility of the laser Doppler technique were performed on six subjects attending for routine endoscopy. These subjects had blood flow measured at six points in the antrum and six in the fundus of the stomach over a 10 second period as described above. In addition, blood flow was measured at one par-ticular point over 10 seconds on three occasions, withdrawing the probe from the mucosa between measurements. Results are given in Table I (FIG 2) Fundal mucosal blood flow was significantly higher than that in the antrum (p<0 001). reduced in the fundus (p<0-001) and antrum (p<0 002) of the stomach after 24 hours' indomethacin intake -the time of maximal mucosal damage. By day 7 blood flow had increased: it was still significantly less than the value before treatment in the fundus (p<002) but not in the antrum (p=008). By day 28, the time of endoscopic mucosal recovery, blood flow was not significantly different to that before treatment. There was no change in blood flow in the three control subjects over the 28 days of the study.
To determine the correlation between the severity of mucosal damage and the change in blood flow, it was necessary to regrade the endoscopic damage. This was done by using the original grading criteria but grading damage separately for fundus and antrum on a scale of 0 (normal) to 4 (severe damage±ulceration). This is because the original grading system did not differentiate between antral and fundal damage. There is a good correlation (r=0 76) between the severity of mucosal damage and the percentage change in mucosal blood flow after 24 hours of indomethacin intake, the time of maximal mucosal damage (Fig 3) .
PGE2 METABOLISM (FIG 4) PGE2 in mucosal homogenate was measured in 10 of our volunteers. Total PGE2 content was significantly higher in the antrum than in the fundus ofthe stomach (antrum, mean (SEM): 83 (21) and fundus: 36 (11) pmol/mg of protein, n= 10, p<0 05 (unpaired t)). After 24 hours' indomethacin, PGE2 content was significantly reduced from values before treatment in both the fundus and antrum (antrum: 30 (9) and fundus: 21 (7) pmol/mg of protein, n=10, p<0-01 for reduction in both fundus and antrum). By day 7, when endoscopic damage was improving, PGE2 content remained significantly reduced compared with values before treatment (mean (SEM) 43 (13) in antrum and 24 (8) in fundus, n= 10, p<001 for both fundus and antrum). In spite of mucosal recovery by day 28, PGE2 content remained significantly reduced (36 (16) in the antrum and 22 (12) in the fundus, n= 10, p<0 01 for difference between fundal and antral values between values before treatment and 28 days). There was no correlation between the fall in PGE2 content and the severity of the mucosal damage after 24 hours' indomethacin, the time of maximal damage (r= -0 34). In the three control subjects, there was no change in the PGE2 content of mucosal homogenates during the study period. During the 28 days of the study there was no significant change in mucosal PGE2 degredation capacity (Table II) .
Discussion
Our results confirm previous findings24 that indomethacin (50 mg three times daily) produces acute gastroduodenal damage in all subjects and that with continued administration endoscopic damage resolves. This adaptation to damage appears at day 7 and is complete by day 28, although not all subjects exhibit complete resolution of injury. Two of our volunteers had persistent grade 2 mucosal damage at day 28, although in both of these it was less than that after 24 hours of drug administration. It is unclear why mucosal damage failed to resolve in these two subjects, both were non-smokers, drank less than 40 g of alcohol per day, and had no other features to differentiate them from other volunteers.
Adaptation includes healing of the acute injury and enhancement of mucosal defence to prevent further damage during continued exposure to the damaging agent and has been well described in a variety of animal models and to a range of injurious agents.22 This phenomenon was initially attributed to increased generation of 'protective' mucosal prostaglandins,22 although recently this has been questioned.30 18 In addition, we have found a good correlation between the severity of the mucosal damage and the magnitude of the reduction in mucosal blood flow. It has been suggested that endogenous prostaglandins contribute to the maintenance of basal gastric mucosal blood flow in animals and man.'9 Thus, reduction of endogenous prostaglandins by indomethacin's cyclo-oxygenase inhibitory action may explain the reduction in gastric mucosal blood flow seen in our subjects. It could be hypothesised that endogenous prostaglandin reduction by oral indomethacin is not uniform, possibly because of greater inhibition of mucosal cyclo-oxygenase in areas with greater local concentrations of indomethacin. This, coupled with more generalised reductions in mucosal defence -for example reduced bicarbonate secretion and reduced surface hydrophobicity -may result in the focal damage described.
In our studies, mucosal recovery was associated with a return of blood flow to normal despite a continued reduction in PGE2. How mucosal blood flow regulates itself in this situation remains unclear but an increase in blood flow would enhance mucosal defence and repair of injury and contribute to the adaptive process. As the mucosal blood flow was not increased above its values before treatment, however, it is difficult to envisage its role in preventing further damage during continued exposure to the drug. Clearly, other mechanisms play an important role in the adaptive process.
The mechanisms of the initial damage by indomethacin and subsequent adaptation to continued intake therefore remain unknown. The clear evidence of an adaptive response in most subjects should provide further stimulus for defining the mucosal mechanisms responsible for it.
